Wednesday, June 10, 2026

Patent directory · USPTO A61K / A61P

Patents matching “REGENERON PHARMACEUTICALS, INC.”

837 pharma patents match "REGENERON PHARMACEUTICALS, INC." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 837
Index total 30,257
Page 33 / 35

Quick answer

This filtered view shows 837 pharmaceutical patents matching "REGENERON PHARMACEUTICALS, INC." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

837 results for “REGENERON PHARMACEUTICALS, INC.” · 30,257 patents in full index Clear search

  1. US 7396918

    IGF-I fusion polypeptides and therapeutic uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 8, 2008 · Expires Jul 3, 2028

    granted
  2. US 7396664

    VEGF-binding fusion proteins and nucleic acids encoding the same

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 8, 2008 · Expires Jul 3, 2028

    granted
  3. US 7378095

    Methods of treating type I diabetes by blocking VEGF-mediated activity

    REGENERON PHARMACEUTICALS, INC. · Granted May 27, 2008 · Expires May 22, 2028

    granted
  4. US 7374757

    Modified chimeric polypeptides with improved pharmacokinetic properties

    REGENERON PHARMACEUTICALS, INC. · Granted May 20, 2008 · Expires May 15, 2028

    granted
  5. US 7374758

    Modified chimeric polypeptides with improved pharmacokinetic properties and methods of using thereof

    REGENERON PHARMACEUTICALS, INC. · Granted May 20, 2008 · Expires May 15, 2028

    granted
  6. US 7365165

    IL-1 antagonist formulations

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 29, 2008 · Expires Apr 24, 2028

    granted
  7. US 7361350

    Use of an IL-1 antagonist for treating arthritis

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 22, 2008 · Expires Apr 17, 2028

    granted
  8. US 7354580

    Method of administering and using VEGF inhibitors for the treatment of human cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 8, 2008 · Expires Apr 3, 2028

    granted
  9. US 7354582

    Use of VEGF antagonists for the treatment of malignant gliomas

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 8, 2008 · Expires Apr 3, 2028

    granted
  10. US 7355018

    Modified IGF1 polypeptides with increased stability and potency

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 8, 2008 · Expires Apr 3, 2028

    granted
  11. US 7354581

    Therapeutic combination of a VEGF antagonist and anti-hypertensive agent

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 8, 2008 · Expires Apr 3, 2028

    granted
  12. US 7354579

    Method of treating cancer with a VEGF antagonist and an anti-proliferative agent

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 8, 2008 · Expires Apr 3, 2028

    granted
  13. US 7354578

    Method of tumor regression with VEGF inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 8, 2008 · Expires Apr 3, 2028

    granted
  14. US 7351411

    Methods of treating anemia by inhibition of vascular endothelial growth factor (VEGF)

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 1, 2008 · Expires Mar 27, 2028

    granted
  15. US 7309483

    Method of treatment using Tie2 ligand2

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 18, 2007 · Expires Dec 13, 2027

    granted
  16. US 7306799

    Use of VEGF inhibitors for treatment of eye disorders

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 11, 2007 · Expires Dec 6, 2027

    granted
  17. US 7303746

    Methods of treating eye disorders with modified chimeric polypeptides

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 4, 2007 · Expires Nov 29, 2027

    granted
  18. US 7303747

    Use of VEGF inhibitors for treatment of eye disorders

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 4, 2007 · Expires Nov 29, 2027

    granted
  19. US 7303748

    Method of treating eye injury with local administration of a VEGF inhibitor

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 4, 2007 · Expires Nov 29, 2027

    granted
  20. US 7300653

    Method of treating corneal transplant rejection

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 27, 2007 · Expires Nov 22, 2027

    granted
  21. US 7300654

    Method of treating corneal transplant rejection in high risk keratoplasty patients

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 27, 2007 · Expires Nov 22, 2027

    granted
  22. US 7285532

    Therapeutic method for treating bone formation diseases

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 23, 2007 · Expires Oct 18, 2027

    granted
  23. US 7279159

    VEGF inhibitor polypeptides

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 9, 2007 · Expires Oct 4, 2027

    granted
  24. US 7241739

    Morphogenic protein

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 10, 2007 · Expires Jul 5, 2027

    granted